Toll-Like Receptor 4 Activation in Cancer Progression and Therapy
Open Access
- 3 November 2011
- journal article
- review article
- Published by Hindawi Limited in Clinical and Developmental Immunology
- Vol. 2011, 1-12
- https://doi.org/10.1155/2011/609579
Abstract
Cancer immunotherapy has been the focus of intense research since the late 19th century when Coley observed that bacterial components can contribute to cancer regression by eliciting an antitumor immune response. Successful activation and maturation of tumor-specific immune cells is now known to be mediated by bacterial endotoxin, which activates Toll-like receptor 4 (TLR4). TLR4 is expressed on a variety of immune as well as tumor cells, but its activation can have opposing effects. While TLR4 activation can promote antitumor immunity, it can also result in increased tumor growth and immunosuppression. Nevertheless, TLR4 engagement by endotoxin as well as by endogenous ligands represents notable contribution to the outcome of different cancer treatments, such as radiation or chemotherapy. Further research of the role and mechanisms of TLR4 activation in cancer may provide novel antitumor vaccine adjuvants as well as TLR4 inhibitors that could prevent inflammation-induced carcinogenesis.Keywords
This publication has 135 references indexed in Scilit:
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Programming the magnitude and persistence of antibody responses with innate immunityNature, 2011
- Pancreatic adenocarcinoma upregulated factor promotes metastasis by regulating TLR/CXCR4 activationOncogene, 2010
- TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cellsThe EMBO Journal, 2010
- High expression of Toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancerBritish Journal of Cancer, 2010
- TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancerOncogene, 2009
- Innate immune signaling by Toll-like receptor-4 (TLR4) shapes the inflammatory microenvironment in colitis-associated tumorsInflammatory Bowel Diseases, 2009
- Cancer-related inflammationNature, 2008
- Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapyNature Medicine, 2007
- The Hallmarks of CancerCell, 2000